These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2643197)

  • 41. Clinical aspects of monocomponent insulins in the treatment of diabetes.
    Vinik AI; Joffe BI; Seftel HC; Distiller LA; Jackson WP
    S Afr Med J; 1976 Apr; 50(15):587-91. PubMed ID: 1265555
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The correlation between insulin antibodies and circulating immune complexes in diabetics with and without microangiopathy.
    Di Mario U; Ventriglia L; Iavicoli M; Guy K; Andreani D
    Clin Exp Immunol; 1983 Jun; 52(3):575-80. PubMed ID: 6603299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prolonged action of regular insulin in diabetic patients: lack of relationship to circulating insulin antibodies.
    Gardner DF; Wilson HK; Podet EJ; Arakaki RF; Nell LJ; Thomas JW; Crane MM; Field JB
    J Clin Endocrinol Metab; 1986 Apr; 62(4):621-7. PubMed ID: 3512590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A method for determination of anti-insulin antibodies in the plasma of insulin-treated diabetics.
    Sekso M; Resetić J; Riznar V; Solter M
    Acta Med Iugosl; 1978; 32(2):125-34. PubMed ID: 665291
    [No Abstract]   [Full Text] [Related]  

  • 45. Insulin therapy in patients with systemic insulin allergy.
    Mattson JR; Patterson R; Roberts M
    Arch Intern Med; 1975 Jun; 135(6):818-21. PubMed ID: 1130927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different insulin antibody formation in diabetic patients treated with crystallized or highly purified insulins is a transient phenomenon.
    Keilacker H; Rjasanowski I; Woltanski KP; Kohnert KD; Ziegler M; Michaelis D
    Horm Metab Res; 1989 Jul; 21(7):398-9. PubMed ID: 2777200
    [No Abstract]   [Full Text] [Related]  

  • 47. An in vitro approach to the kinetics of insulin antibodies in diabetic patients.
    Ho LT; Wang LM; Chang TC; Fung TJ; Perng JC; Liu YF; Ho T
    Zhonghua Yi Xue Za Zhi (Taipei); 1990 Aug; 46(2):65-72. PubMed ID: 2177366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunologic sensitization of circulating basophils to exogenous insulin in diabetic patients.
    Emanuelli G; Gatti G; Calcamuggi G; Anfossi G; Cotto A; Marcarino C; Camussi G; Ottone G
    Panminerva Med; 1981; 23(2):81-8. PubMed ID: 7033894
    [No Abstract]   [Full Text] [Related]  

  • 49. Insulin-binding antibodies in diabetic patients. Dynamic aspects of their formation.
    Penchev II; Shisheva AC; Ditzov SP; Andreev DC; Sirakov LM
    Acta Diabetol Lat; 1975; 12(5-6):296-302. PubMed ID: 1231464
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin, pancreatic polypeptide, and glucagon antibodies in insulin-dependent diabetes mellitus.
    Asplin CM; Hollander P; Pecoraro RE; Brodsky J; Palmer JP
    Diabetes Care; 1981; 4(3):337-42. PubMed ID: 7047110
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
    Schernthaner G; Borkenstein M; Fink M; Mayr WR; Menzel J; Schober E
    Diabetes Care; 1983; 6 Suppl 1():43-8. PubMed ID: 6343038
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulin antibodies in diabetes.
    Lev-Ran A; Joshua H; Mannheimer S
    Isr J Med Sci; 1971 Sep; 7(9):1035-9. PubMed ID: 5170197
    [No Abstract]   [Full Text] [Related]  

  • 53. Insulin-specific IgE in serum of 67 diabetic patients against human insulin (Novo), porcine insulin, and bovine insulin. Four case reports.
    Falholt K; Hoskam JA; Karamanos BG; Süsstrunk H; Viswanathan M; Heding LG
    Diabetes Care; 1983; 6 Suppl 1():61-5. PubMed ID: 6343042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exogenous insulin needs. Relationship with duration of diabetes, C-peptidemia, insulin antibodies, and retinopathy.
    Haumont D; Dorchy H; Toussaint D; Despontin M
    Helv Paediatr Acta; 1982 May; 37(2):143-50. PubMed ID: 7047466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heterogeneity and specificity of human anti-insulin antibodies determined by isoelectric focusing.
    Thomas JW; Virta VJ; Nell LJ
    J Immunol; 1985 Feb; 134(2):1048-52. PubMed ID: 3880786
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastric inhibitory polypeptide in obesity and diabetes mellitus.
    Service FJ; Rizza RA; Westland RE; Hall LD; Gerich JE; Go VL
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1133-40. PubMed ID: 6373812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Changes of insulin antibody binding ability during monocomponent insulin therapy].
    Araki S; Sasai T; Shichiri M; Yoshikawa R; Hoshi M
    Horumon To Rinsho; 1977 Jan; 25(1):55-60. PubMed ID: 557390
    [No Abstract]   [Full Text] [Related]  

  • 58. The immunogenic properties of a highly purified insulin preparation.
    Manning NT; Drury MI
    Ir J Med Sci; 1979 Apr; 148(4):135-9. PubMed ID: 393651
    [No Abstract]   [Full Text] [Related]  

  • 59. Immunogenicity of bovine, porcine and semisynthetic human insulin.
    Venekamp WJ; van der Hooft JC; Jacobsen L; van Schaik CL
    Neth J Med; 1985; 28 Suppl 1():57-8. PubMed ID: 3892343
    [No Abstract]   [Full Text] [Related]  

  • 60. Serum insulin, insulin antibodies and insulin requirement in the first period of insulin treatment in non-insulin resistant diabetics.
    Lev-Ran A; Ratt L; Gersht N
    Acta Diabetol Lat; 1975; 12(1):66-71. PubMed ID: 1229807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.